HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Business News: Orkla Acquires Healthspan, Bayer Invests Locally, Ipsen Targets Baltics

Executive Summary

A round-up of the latest European consumer health business news: Norway's Orkla strengthens its supplements offering with acquisition of UK's Healthspan; Bayer makes investment commitment to German Consumer Health operation; and Ipsen strikes a deal to promote brands in the Baltics.

You may also be interested in...



UK Marketing Round-Up: Launches From Healthspan, Lanes, A Vogel And Dermal

Healthspan adds New Zealand blackcurrant supplement to Elite range; Lanes Health brings Nordic iron supplement to UK, A Vogel offers British consumers an eco-friendly eye dropper version of Pollinosan; and Dermal Laboratories launches Doublebase Once.  

Bayer Beats The Market In 2021 And Has High Hopes For 2022

Bayer Consumer Health posted sales up 6.5% in 2021 as strong demand for supplements and successful launches helped it grow faster than the global market. The company believes it can deliver up to 5% sales growth in 2022 driven by the upcoming launch of Astepro Allergy in the US and the return of the cough & cold category.

EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year

Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.

Related Content

Topics

UsernamePublicRestriction

Register

RS152290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel